A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
ClinicalTrials.gov · NCT07881783 · Registry updated: 2026-11-20
- Condition / research focus
- Plaque Psoriasis
- Sponsor
- Novartis Pharmaceuticals
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2026-10-30. Completion: 2027-03-31 (may be estimated). No results posted in this registry response.
Products and interventions (0)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Novartis
East Hanover, New Jersey, United States
Site recruitment: Not reported